Cancer drug Dasatinib: New research unearths anti-diabetic properties

Dasatinib is a targeted therapy medication used to treat certain cases of chronic myelogenous leukaemia and acute lymphoblastic leukaemia. A new retrospective cohort study of enterprise-wide Mayo Clinic patients enabled by Informatics for Integrating Biology at the Bedside has claimed that this cancer drug may have antidiabetic effects comparable to medications used to treat diabetes.

The study has suggested that this finding can pave the way for the use of Dasatinib as a novel diabetic therapy. However, more studies are needed to determine whether these results apply to patients with type 2 diabetes mellitus who don’t have underlying malignant diseases. The studies will help establish whether the antidiabetic effects of dasatinib are due to its senolytic properties.

Read more about the study at: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00554-1/fulltext